Evidence map›Paper›PMID 32290546›Full record

ArticleCells2020

Detection of Human CD38 Using Variable Lymphocyte Receptor (VLR) Tetramers.

Srijit Khan, Yanling Liu, Laura M Ernst, Leslie Y T Leung, Patrick Budylowski, Shilan Dong, Paolo Campisi, Evan J Propst, Nikolaus E Wolter, Eyal Grunebaum and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Srijit KhanDepartment of Immunology, University of Toronto, Toronto, ON M5S 1A1, Canada.
Yanling LiuDepartment of Immunology, University of Toronto, Toronto, ON M5S 1A1, Canada.
Laura M ErnstDepartment of Immunology, University of Toronto, Toronto, ON M5S 1A1, Canada.
Leslie Y T LeungDepartment of Immunology, University of Toronto, Toronto, ON M5S 1A1, Canada.ORCID 0000-0002-4883-582X
Patrick BudylowskiDepartment of Immunology, University of Toronto, Toronto, ON M5S 1A1, Canada.
Shilan DongDepartment of Immunology, University of Toronto, Toronto, ON M5S 1A1, Canada.
Paolo CampisiDepartment of Otolaryngology-Head and Neck Surgery, Hospital for Sick Children and University of Toronto, Toronto, ON M5G 1X8, Canada.
Evan J PropstDepartment of Otolaryngology-Head and Neck Surgery, Hospital for Sick Children and University of Toronto, Toronto, ON M5G 1X8, Canada.
Nikolaus E WolterDepartment of Otolaryngology-Head and Neck Surgery, Hospital for Sick Children and University of Toronto, Toronto, ON M5G 1X8, Canada.
Eyal GrunebaumDivision of Immunology and Allergy, Hospital for Sick Children and University of Toronto, Toronto, ON M5G 1X8, Canada.
Mario OstrowskiDepartment of Immunology, University of Toronto, Toronto, ON M5S 1A1, Canada.
Götz R A EhrhardtDepartment of Immunology, University of Toronto, Toronto, ON M5S 1A1, Canada.ORCID 0000-0002-5868-5191
University of Toronto · CA

Funding

Discovery of novel surface biomarkers of latently HIV-infected cells using lamprey antibody technologyR01AI117818 · NIAID · UNIVERSITY OF TORONTO · PI EHRHARDT, RUDOLF ARNOLD GOETZ, OSTROWSKI, MARIO · 2015 to 2017
$647k
NIAID NIH HHS R01 AI117818
6 · The paper itself

Abstract

CD38 is a multifunctional cell surface receptor expressed on multiple cell lineages of hematopoietic origin with high levels of expression on human plasma cells. Previously, we isolated the monoclonal variable lymphocyte receptor B (VLRB) MM3 antibody from the evolutionarily distant sea lamprey, which recognized the CD38 ectoenzyme exclusively on human plasma cells in a manner that correlated with CD38 enzymatic activity. The plasma cell-specific binding of VLRB MM3 contrasts with the broad pattern of expression of CD38-determined conventional antibodies specific for this antigen. In an effort to facilitate the application of this unique reagent in combination with conventional antibody panels, we explored a strategy to generate VLRB MM3 tetramers. The resulting reagent maintained the threshold-based recognition of CD38. Increased sensitivity achieved with VLRB MM3 tetramers also showed preferential recognition of germinal center centroblasts over centrocytes. VLRB MM3 tetramers thus provided a unique and versatile single-step staining reagent for the detection of human CD38 that is readily incorporated into multi-color flow cytometry panels.

Indexed as

ADP-ribosyl Cyclase 1Flow CytometryHumansLymphocytesModels, MolecularADP-ribosyl Cyclase 1evolutionflow cytometrytetramervariable lymphocyte receptor (VLR)

Identifiers

PMID32290546
PMCPMC7226959
OpenAlexW3015497457

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.